Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
Pharmaceutical
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Atosiban / RW-22164 CAS 90779-69-4 Raw Materials Powder
Product Overview:
Atosiban Powder is a combined contractin and pressin V1A receptor antagonist. the contractin receptor is structurally similar to the pressin V1A receptor. rw-22164 powder is also a deamino oxytocin analogue. atosiban CAS 90779-69-4 is a major contraction inhibitor and may be used in studies of spontaneous preterm labor. Atosiban Powder is used as a competitive antagonist of the cyclic peptide oxytocin receptor in the uterus and on the meconium and fetal membranes.
Atosiban / RW-22164 CAS 90779-69-4 Raw Materials Powder Attributes
CAS: 90779-69-4
MF: C43H67N11O12S2
Specification: 99% min Atosiban / RW-22164 Powder
Sample: Atosiban / RW-22164 Powder
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Atosiban / RW-22164 CAS 90779-69-4 Raw Materials Powder Details
Atosiban / RW-22164 Powder Usage and Synthesis.
Atosiban, as a combined receptor antagonist of contractin and pressin V1A, has a similar chemical structure and high affinity for both receptors, competitively binding to contractin and pressin V1A receptors, thereby blocking the pathway of action of contractin and pressin and reducing uterine contractions.
Atosiban Powder is a combined contractin and pressin V1A receptor antagonist. the contractin receptor is structurally similar to the pressin V1A receptor. rw-22164 powder is also a deamino oxytocin analogue. Atosiban CAS 90779-69-4 is a major contraction inhibitor and may be used in studies of spontaneous preterm labor. Atosiban Powder is used as a competitive antagonist of the cyclic peptide oxytocin receptor in the uterus and on the meconium and fetal membranes.
Applications of Atosiban / RW-22164 Powder.
Atosiban is a drug for the treatment of psychiatric disorders, mainly for the treatment of schizophrenia, bipolar disorder, depression, obsessive-compulsive disorder, and anxiety disorders. Its main effects include:
1. antipsychotic effect: Atosiban can reduce psychotic symptoms such as hallucinations, delusions and thought disorders, and improve the cognitive and emotional state of patients.
2. Sedative effect: Atosiban can reduce patients' irritability, restlessness and nervousness, and make them feel calm and relaxed.
3. Antidepressant effect: Atosiban can improve patients' depressed mood, low self-esteem, helplessness and other depressive symptoms, and improve their state of mind and quality of life.
4. Anti-anxiety effect: Atosiban can reduce patients' anxiety, fear, tension and other emotions, making them feel more confident and calm.
5. Improvement of sleep: Atosiban can improve patients' sleep quality and relieve insomnia and other problems.
In conclusion, atosiban is a safe and effective drug that can help patients relieve the symptoms of mental illness and improve their quality of life. However, patients should follow medical advice when using the drug and pay attention to the dosage and duration of administration to avoid adverse reactions and dependence problems.
Pharmacological Effect of Atosiban / RW-22164 Powder.
Atosiban acetate is a disulfide-bonded cyclic polypeptide consisting of 9 amino acids, a molecule of condensin modified at positions 1, 2, 4 and 8. The N-terminal of the peptide is 3-mercaptopropionic acid (the sulfhydryl group forms a disulfide bond with the sulfhydryl group of [Cys]6), the C-terminal is in the form of an amide, and the second amino acid at the N-terminal is the ethylated modified [D-Tyr(Et)]2. Atosiban acetate exists as an acetate in the pharmaceutical form , the generic name of which is atosiban acetate.
Atosiban is a combined contractin and pressin V1A receptor antagonist, and the contractin receptor is structurally similar to the pressin V1A receptor. When the contractile hormone receptor is blocked, contractile hormone can still act through the V1A receptor, so it is necessary to block both receptor action pathways, and a single antagonist of one receptor can effectively inhibit uterine contraction. This is one of the main reasons why beta agonists, calcium channel blockers and prostaglandin synthase inhibitors are not effective in suppressing uterine contractions.